TA Associates: Novo Holdings and TA Associates partner with Biocomposites to drive next chapter of its growth

Additional investment and resources will accelerate Biocomposites' international expansion and innovation in products for use in infection managementHELLERUP, Denmark, LONDON and KEELE, England, March 3, 2025 /PRNewswire/ -- Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to make an investment in Biocomposites ("the Company"), an international medical devices company that engineers, manufactures and markets leading products for use in infection management in bone and soft tissue. As part of the transaction TA, Biocomposites' majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites' management. The transaction gives TA and Novo Holdings shared control of Biocomposites.Headquartered in Keele, United Kingdom, Biocomposites' pioneering calcium compounds and specialty polymer products - including STIMULAN, the only calcium matrix carrier platform approved to carry antibiotics into infected and non-infected sites in bone and soft tissue - are trusted by surgeons in over 100 countries worldwide. With over 30 years of expertise, Biocomposites' advanced solutions are used in more than one million procedures annually, across multiple specialties including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, and sports injuries.Since partnering with TA in 2017, Biocomposites has achieved significant growth - including a threefold increase in revenues, successful geographic expansion, and continued product diversification. The Company has also completed two strategic acquisitions, strengthening its international presence and enabling entry into adjacent indications and therapeutic areas. With the new investment from Novo Holdings and the ongoing support of TA, Biocomposites aims to build on this momentum, deepening its global footprint and further advancing its pipeline of innovative products to deliver life-changing solutions at scale."We are thrilled to partner with Biocomposites and TA in this exciting new chapter for the Company," said Henrik ...Full story available on Benzinga.com